Jeff Musgnung | Psychiatrist.com

Article

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Original Research

A Pooled Analysis of Gender and Trauma-Type Effects on Responsiveness to Treatment of PTSD With Venlafaxine Extended Release or Placebo

Original Research

Venlafaxine Extended Release in the Short-Term Treatment of Depressed and Anxious Primary Care Patients With Multisomatoform Disorder

Article

Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder

Here, review results from a post hoc analysis that evaluated the tolerability of long-term desvenlafaxine for major depressive disorder at discontinuation using a taper regimen compared with abrupt discontinuation.Â

Original Research

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

Original Research

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases